









Markets
/
Stocks
/
nasdaq-iron
/

Disc Medicine Inc

IRON

85.075USD

+1.495+1.79%

Market hours （ET）Quotes delayed by 15 min

2.98BMarket Cap

LossP/E TTM



Disc Medicine Inc

85.075

+1.495+1.79%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Disc Medicine Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Disc Medicine Inc's Score

Industry at a Glance

Industry Ranking

181 / 501

Overall Ranking

321 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

115.917

Target Price

+38.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Disc Medicine Inc Highlights

StrengthsRisks

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -20.09, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.67M shares, decreasing 8.78% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 6.08K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Disc Medicine Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -20.09, which is -56.23% below the recent high of -8.79 and -0.32% above the recent low of -20.16.

Score

Industry at a Glance

Previous score

6.82

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 181/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Disc Medicine Inc is 110.00, with a high of 153.00 and a low of 85.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

115.917

Target Price

+38.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Disc Medicine Inc

IRON

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.41, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 102.10 and the support level at 71.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.18

Change

0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.922

Neutral

RSI(14)

55.561

Neutral

STOCH(KDJ)(9,3,3)

25.071

Sell

ATR(14)

3.437

High Vlolatility

CCI(14)

-116.325

Sell

Williams %R

83.497

Oversold

TRIX(12,20)

0.893

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

85.760

Sell

MA10

85.807

Sell

MA20

84.594

Buy

MA50

72.176

Buy

MA100

64.936

Buy

MA200

57.337

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 99.74%, representing a quarter-over-quarter decrease of 7.50%. The largest institutional shareholder is PRFDX, holding a total of 1.49M shares, representing 4.30% of shares outstanding, with 7.02% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

3.08M

+1.02%

Access Industries, Inc.

3.56M

Atlas Venture

2.15M

-9.88%

BlackRock Institutional Trust Company, N.A.

1.71M

-2.20%

Frazier Life Sciences Management, L.P.

1.65M

-5.70%

RA Capital Management, LP

1.58M

Janus Henderson Investors

1.55M

+9.18%

T. Rowe Price Associates, Inc.

Star Investors

1.49M

+11.58%

The Vanguard Group, Inc.

Star Investors

1.39M

+6.98%

Wellington Management Company, LLP

1.43M

-38.89%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.